tbuckley/cabot-search huggingface dataset:
KEEPING IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS IN CHECK: SIMULTANEOUS VENOARTERIAL ECMO AND IMPELLA SUPPORT AS A BRIDGE TO RECOVERY
Authors: Ashley Stein-Merlob, Jeffrey Hsu, Bradley Colton, Christopher Berg, Allison C. Ferriera, Arnold Baas, Mario Deng, Rushi Parikh, Eric Yang
Journal: Journal of the American College of Cardiology (2020)
THE USEFULNESS OF VESSEL FRACTIONAL FLOW RESERVE FOR ASSESSING CARDIAC GRAFT VASCULOPATHY IN HEART TRANSPLANT RECIPIENTS
Authors: Sakura Nagumo, Carlos Collet, Emanuele Gallinoro, Alessandro Candreva, Giovanni Monizzi, Takuya Mizukami, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek, Jeroen Sonck, Bernard De Bruyne, Marc Vanderheyden
Journal: Journal of the American College of Cardiology (2020)
Resource use and costs in the last year of life among Medicare beneficiaries who died from prostate cancer versus with the disease between 2000 and 2007.
Authors: Shelby D. Reed, Michaela A Dinan, Yanhong Li, Yinghong Zhang, Lesley H Curtis, Daniel J. George, Suzanne B Stewart
Journal: Journal of Clinical Oncology (2013)

6631 Background: Prostate cancer is one of the leading sources of overall cancer care costs among men in the United States. Medical resource use and costs associated with prostate cancer care at the end of life, remain poorly understood. Methods: Retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) -Medicare data was used to characterize changes in resource utilization and health care costs to the Centers for Medicare and Medicaid (CMS) in patients diagnosed with prostate cancer who died of prostate cancer vs. non-prostate causes between 2000 and 2007. Results: A total of 34,727 patients with prostate cancer met study criteria. Patients who died of prostate cancer were significantly more likely to have been diagnosed with incident distant metastatic disease (27% vs. 4%) and had fewer comorbid conditions than patients who died of other causes. In the year prior to death, men who died of prostate cancer had lower mean inpatient costs ($20,769 vs. $29,851), resulting from fewer hospitalizations (1.8 vs. 2.1) and fewer days spent in the hospital (12.2 vs. 15.7) and the ICU (1.4 vs. 3.4) as compared to men who were diagnosed with prostate cancer but died of some other cause (all P&lt; 0.001). Men who died of prostate cancer also had lower rates of SNF utilization (32.8% vs 36.2%) and spent fewer days in SNF institutions (11.7 vs 14.7) (both P&lt; 0.001). Conversely, men who died of prostate cancer were more likely to have enrolled in hospice (62% vs. 28%) with higher mean hospice costs ($5,117 vs. $1,981) (both P&lt; 0.001). The substitution of more hospice care relative to inpatient care for men who died of prostate cancer resulted in lower total health care costs ($42,572 vs. $45,830; P&lt; 0.001) relative to men who died from non-prostate cancer causes. Conclusions: Among men with a diagnosis of prostate cancer who died between 2000 and 2007, those with prostate cancer-specific mortality had lower overall health care costs than those who died from other causes. Less aggressive inpatient care near the end of life may explain the differences in cost. Ongoing investigation of care at the end of life is warranted given recent changes in the treatment landscape of metastatic prostate cancer.
Response to Jefford
Authors: Larissa Nekhlyudov, Lawrence N Shulman, Paul B Jacobsen, Michelle A Mollica, Ann M Geiger, Deborah K Mayer
Journal: JNCI Journal of the National Cancer Institute (2019)

We appreciate the letter by Dr Michael Jefford in response to our recent paper describing the quality of cancer survivorship framework.As he points out, we specifically developed it to provide "an essential reference, to build and assess survivorship care efforts."The issues he raises are relevant in delivering survivorship care using this framework.Dr Jefford brings up an important point regarding clinician burnout, which is becoming prevalent in the United States and internationally (1,2).Solutions to this problem are being addressed by the National Academy of Medicine Action Collaborative on Clinician Well-Being and Resilience, a network of more than 60 organizations convened in 2017 (2).In cancer survivorship care, finding ways to reduce burden on health-care providers will need specific attention when developing and testing models of follow-up (3).Transitioning survivors from oncology specialists to survivorship clinics or primary care providers may leave them seeing more patients on active treatment or at the end of life and may potentially curb the "joy" of seeing long-term "success" survivors.However, failing to transition may lead to additional workload of caring for large panels of long-term survivors and thus increase stress and burnout.Caring for cancer survivors with complicated histories, treatment exposures, and chronic medical conditions may also endanger the well-being of primary care clinicians.The nursing workforce in all settings is being threatened (4).Our framework allows for flexible methods of assessing and monitoring the suggested domains and developing innovative approaches in doing so.It takes into consideration not only the patients and their needs, but also the providers and systems supporting survivorship care.Sustaining and increasing a workforce to meet the needs of the growing population of cancer survivors is critical, and organizations may consider adopting the ongoing calls to expand the Institute for Healthcare Improvement's "Triple Aim" to a "Quadruple Aim" that also seeks to improve the work life of health-care providers (5).We fully support the widely accepted definition of cancer survivor as an individual from the time of diagnosis and through the balance of his or her life (6).Therefore we agree with Dr Jefford
Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting.
Authors: Giorgio Mustacchi, Annamaria Molino, Elena Fiorio, Antonella Brunello, Vittorina Zagonel, Antonella Ferro, Alessia Caldara, Aldo Iop, Salvatore Bonura, Micaela Stefani, Daniele Bernardi
Journal: Journal of Clinical Oncology (2012)

586 Background: Relapse Rate (RR) after adjuvant trastuzumab (AT) reported in clinical trials is between 15 and 21%. Information on RR and clinical behaviour of HER2-POS metastatic disease after AT outside clinical trials is limited. At ASCO Meeting 2010 RR was reported 8% (Abs 1080) to 10% (Abs 684), with a Survival Post Progression (SPP) of 8.8 and 5.7 months, respectively. It is useful to increase informations about metastatic HER2-POS disease after AT, outside clinical trials. Methods: HER2-POS consecutive cases treated with AT in 6 Hospitals of North East Italy were anonymously collected and merged. The following data were analyzed: Stage, ER/PgR Status, Chemotherapy regimens (CHT) , follow up, RR, Disease Free Survival (DFS), Overall Survival (OS) and SPP. Results: The number of patients was 413, median age 55 (24-84). Anatomic Stage was I in 39.7%, II in 40,3%, III in 24.4%. ER/PgR neg cases were 164 (41.6%). Given CHT were Anthra-based 33.4% and Anthra-Taxane 54.5%. At a mean follow up of 35 months (7-115) RR was 10.8% (45 cases), with a mean DFS of 23.8 months (3.2-74). Among relapsed patients, 37/45 (82.2%) had ER/PgR neg tumors. One patient died NED for CHF and 22 for metastatic disease, with a mean OS of 37.1 months (10.2-87.9). Mean SPP was 17.8 months. According to DFS &lt;12 mos , &gt;12&lt;24 and &gt;24, mean OS was 31.3, 31.7 and 56.12(p=0.03) months; SPP was 24.2, 14.4 and 17.8 months, respectively. Conclusions: In our experience RR after AT is lower than in published Phase III clinical trials. ER/PgR neg status seems a negative prognostic factor (82.2% in the relapsed population vs 41.6% overall). OS is similar for patients relapsed within 24 months but SPP is 10 months longer in very early relapses. Relapse after 2 years is correlated with a long OS (nearly 5 years), with SPP shorter vs early relapse (17.8 vs 24.2 months). Our preliminary results suggest different disease behaviors in relapsed HER2-POS Breast Cancer after AT, with different DFS and SPP, suggesting a different effect of further therapies. Considering the small RR, the study target accrual is proceeding to collect up to more than 1000 AT treated patients, including post-progression treatments, not available at the moment.
THE SGLT2 INHIBITOR EMPAGLIFLOZIN CAUSES A GREATER REDUCTION IN SKIN SODIUM CONTENT AND INTERSTITIAL VOLUME THAN LOOP DIURETICS IN HEART FAILURE
Authors: Carlos G. Santos-Gallego, Juan Antonio Requena Ibanez, Rodolfo San Antonio, Maria Belen Picatoste Botija, Kiyotake Ishikawa, Torsten Vahl, Angel Sanz Salvo, Valentin Fuster, Juan J. Badimon
Journal: Journal of the American College of Cardiology (2020)
REPEATABILITY OF QUANTITATIVE PERICORONARY ADIPOSE TISSUE ATTENUATION AND CORONARY PLAQUE BURDEN FROM COMPUTED TOMOGRAPHY ANGIOGRAPHY USING A SEMI-AUTOMATED METHOD
Authors: Priscilla McElhinney, Evangelos Tzolos, Michelle Williams, Sebastien Cadet, Marc Dweck, Daniel S. Berman, Piotr Slomka, David E. Newby, Damini Dey
Journal: Journal of the American College of Cardiology (2020)
QUANTIFYING THE CHALLENGE OF UNTREATED SEVERE HYPERLIPIDEMIA: THE CORCAL VANGUARD TRIAL
Authors: Jeffrey L. Anderson, Viet T. Le, Heidi May, Kevin Johnson, Shanelle Cripps, Lesley Schwab, Shelbi Braun, Fidela L. Moreno, Donald Lappe, Kirk Knowlton, J. Brent Muhlestein
Journal: Journal of the American College of Cardiology (2020)
BPI20-007: Evaluation of Guideline Adherence in Colorectal Cancer Management in a Private Clinic, Lima – Peru
Authors: Karina Mayra Aliaga, Fradis Gil-Olivares, Laura Pérez, Gisely Hijar, Edward López, Cindy Alcarraz, Mariana Serrano, Claudio Flores, Alonso Díaz, Jose Gutierrez, Alfredo Aguilar
Journal: Journal of the National Comprehensive Cancer Network (2020)
Efficacy of exemestane and everolimus in HR positive (including HER2-neu positive) heavily pretreated cases of metastatic breast cancer in north India.
Authors: Shyam Aggarwal, Prashant Yadav, Krishna Rawat, Sunita Bhalla
Journal: Journal of Clinical Oncology (2013)

e11546 Background: M-Tor pathway is deregulated in significant percentage of patients with breast cancer. This pathway is responsible for tumor growth and metastasis especially in hormone receptor (HR) positive cases. Thus dual blockade of estrogen and M-Tor pathway has shown efficacy in this setting. Methods: Twenty patients with hormone receptor positive metatstatic breast cancer were treated with combination of everolimus 5 mg and exemestane 25 mg daily since November 2011. The median age was 53 years (age range- 32 to 75 years). All patients had two more sites of metastasis. 14 cases had 3 or more sites of metastasis. Liver- 10, lungs – 15, bones – 12, skin -3, lymph nodes – 10, and CNS – 5. Six of twenty cases were Her2 neu positive and were pretreated with Herceptin and lapatinib. All except 2 patients were treated with chemotherapy, 13 with minimum three lines of chemotherapy. All patients were ER and or PR positive and preteated with tamoxifen (5) and or aromatase inhibitors (anastrozole 9 and letrozole 11). The time gap between starting exemestane and everolimus and onset of metastatic disease was 2.5 years. Results: 7 out of 20 patients achieved disease control (either partial response-6 or stable disease -1). Out of 6 cases who were her2 neu positive, two achieved partial response. 5 out of 20 cases survive beyond nine months. Only two patients could go on to 10 mg daily everolimus. The dose limiting toxicity was development of oral ulcers. One patient had fever. No case of pneumonitis was noted with this dose. Conclusions: Combination of everolimus and exemestane is effective in HR positive cases and also in Her2 neu positive cases. 5 mg everolimus is well tolerated by most women. There is a need to further study the efficacy of this combinantion in Her2 neu positive cases.
Screening and Prophylactic Amiodarone Reduces Post-Operative Atrial Fibrillation in At-Risk Patients
Authors: Terrence Pong, Kevin Cyr, John Niesen, Joy Aparicio-Valenzuela, Cody Carlton, Michael P. Fischbein, Y. Joseph Woo, Jack H. Boyd, Anson M. Lee
Journal: Journal of the American College of Cardiology (2020)
MECHANISM OF AUGMENTED SYSTOLIC ANNULAR EXPANSION IN LATE SYSTOLIC MITRAL VALVE PROLAPSE: ASSESSMENT OF THE PAPILLARY MUSCLES AND LEAFLET DYNAMICS BY ECHOCARDIOGRAPHY WITH SPECKLE TRACKING ANALYSIS
Authors: Soshi Hei, Mai Iwataki, Takeshi Onoue, Atsushi Hayashi, Yutaka Otsuji
Journal: Journal of the American College of Cardiology (2020)
Liver Steatosis Secondary to PRRT With 177Lu-DOTATATE
Authors: Beatriz Matheos de Lima, Juliana Ribeiro de Carvalho, Priscilla Romano Gaspar, Priscilla Brunelli Pujatti, Rinaldo Gonçalves
Journal: Clinical Nuclear Medicine (2020)

PRRT (peptide receptor radionuclide therapy) with Lu-DOTATATE for neuroendocrine tumor has some well-known adverse effects, concerning specially the bone marrow and kidneys. Hepatotoxicity has been rarely reported, and there are no data regarding hepatic steatosis secondary to PRRT. We reviewed upper abdomen CT and MRI and applied radiologic criteria for the diagnosis of hepatic steatosis on 62 patients treated between the years of 2010 and 2017. Two patients already showed radiologic signs of steatosis in the middle of the treatment and through follow-up all patients showed improvement of the steatosis.
Prophylactic anticonvulsants in patients (pts) with primary brain tumor (PBT): Have we really agreed to a consensus?
Authors: Julia Andrade De Oliveira, Iuri Amorim De Santana, Inacelli Queiroz de Souza Caires, Rafael Caires-Lima, Vanessa Costa Miranda, Bruno Mendonça Protásio, Lucila Soares Da Silva Rocha, Henrique Faria Braga, Ana Cristina Malacarne Mencarini, Manoel Jacobsen Teixeira, Luiz Henrique Martins Castro, Olavo Feher
Journal: Journal of Clinical Oncology (2013)

2060 Background: Routine prophylactic antiepileptic drugs (AED) use to prevent seizures in PBT seizure-naïve pts is not supported by current guidelines. However, the best management of prophylactic AED started in the perioperative setting is still unclear. Additionally, AED can have serious side effects, might have a negative impact on cognition and may present significant drug interactions. Little is known about actual current practice patterns regarding prophylactic AED in PBT. In this report we investigated prophylactic AED use in a tertiary care institution. Methods: We reviewed medical files of 260 consecutive patients, registered in our center between 2008 and 2012, focusing on prophylactic AED use. Collected data included: patient demographics, starting date, AED type, and indication. A descriptive analysis was performed with SPSS IBM version 20.0. Results: Median age was 44.5 years (11 - 83). Most pts had an ECOG PS ≤ 1 (76.4%). Overall, AED were used by 218 pts. Most common agents were: phenytoin (68.8%), carbamazepine (27.1%) and phenobarbital (16.1%). Among 141 seizure-naïve pts, 99 (70.2%) received AED as primary prophylaxis (PP). Only 14 pts (14.1%) had the drug eventually discontinued, in a median time of 5.9 months (1.1 – 76.8m). AED were used as PP in 60% of pts with low-grade gliomas, 73.3% with anaplastic gliomas and 93.9% with glioblastomas. Twenty-seven pts (27.3%) on PP presented seizures, generally associated with tumor progression. For most of them a new anticonvulsant was added for seizure control. Of the 42 seizure-naïve pts who did not receive prophylactic AED, only two presented seizures during or within the first week post-radiotherapy. Conclusions: In our study population, prophylactic AED use in PBT was extremely high (70.2% of seizure-naive pts). Postoperatively, AED were discontinued in a small minority of pts, and even so, only after a prolonged period of time. Very few seizures occurred in pts not receiving prophylactic AED. Our results suggest that practice patterns regarding prophylactic AED in PBT still contradict established guidelines.
OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE AORTIC STENOSIS AND DIASTOLIC DYSFUNCTION
Authors: Hassan M. Alharbi, Mohammed Alotaiby, Mohammed AlAhmari, Abdulrhaman Alanazi, Bander AL Ghamdi, Abdullah Alsuayri, Ahmed Alhaydhal, Amr A. Arafat, Khaled D. Algarni
Journal: Journal of the American College of Cardiology (2020)
Early use of home health care on health care utilization for patients with advanced lung cancer.
Authors: Steven Rousey, Kiran Krishan Lassi, Jodi Wieczorek, James Essler, Marie Brown, Sylvia Haroldson, Sue Sheppard, Kari Olson, Michelle O'Brien, Yunfei Wang
Journal: Journal of Clinical Oncology (2013)

e19015 Background: Patients with advanced lung cancer historically have required significant use of health care resources including hospitalizations, ICU admissions and emergency room visits which are often related to inadequately controlled symptoms. Most patients with advanced lung cancer prefer to remain in their own home as much as possible and are willing to work with home nursing resources, if available. The purpose of this pilot study was to determine the effect of early use of home health care on health care utilization for patients with advanced lung cancer. Methods: Betweem May 2011 and May 2012, 18 patients were enrolled in a pilot program to explore early use of home care for individuals with advanced lung cancer. Inclusion criteria consisted of a diagnosis of stage III/IV lung cancer (any histology) and home care eligibility using Medicare criteria. The endpoints were hospitalization rate, number of ICU admissions and emergency room visits. The results were compared to an historical control group (562 patients with advanced lung cancer diagnosed between 2006 and 2011). Binomial confidence interval (CI) was used to estimate the 95% CIs and Fisher's exact test was used to assess the p-values. Results: Results at one year showed the hospitalization rates for the pilot group and the control group were 44% (95% CI, 22-69) and 78% (95% CI, 74-81), respectively (p&lt;0.01) and the ER visit rate was 17% (95% CI, 4-41) and 41% (95% CI, 37-45), respectively (p=0.049). The ICU admission rates were 0% and 11% in the two groups, respectively, and this difference was not statistically significant. Home care visits ranged from 1-77 with an average of 12 visits per patient. The estimated cost of the home care program for the duration of enrollment was $2,330 per patient. Conclusions: Early use of home health care for patients with advanced lung cancer appears to reduce the rates of hospitalization and emergency room visits when compared with historical controls, and though the results were not statistically significant, none of the 18 patients in the pilot group were admitted to the ICU. A larger multi-institutional study will examine the potential of this simple intervention for cost saving, enhanced care quality and improved patient satisfaction.
OUTCOMES OF TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN PROSTHETIC VALVE STENOSIS
Authors: Pratik Agrawal, Muhammad Khan, Bilal Munir, Kinjan Patel, Moinuddin Syed, Mohammed Osman, Yasir Abdul Ghaffar, Sudarshan Balla, Irfan Zeb
Journal: Journal of the American College of Cardiology (2020)
Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy.
Authors: Eric Jay Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Donna Hogge, Martin S. Tallman, Stuart L. Goldberg, Tibor Kovacsovics, Arthur Chin Louie, Jorge E. Cortes
Journal: Journal of Clinical Oncology (2013)

7100 Background: CPX-351 encapsulates cytarabine (CYT) and daunorubicin (DNR) at a 5:1 molar ratio within liposomes, enabling preferential drug uptake within leukemic blasts and intracellular release, potentially enhancing efficacy in AML. A pair of randomized Phase IIb studies in newly diagnosed older patients (pts) and younger 1st relapse AML pts reported improved rates of morphologic leukemia-free state, CR + CRi, and significant improvements in survival among previously untreated high risk (secondary) pts and among poor-risk 1 st relapse pts. This report presents the results of the multivariate analyses performed on all pts treated in both studies. Methods: Patients 60-75 yo with newly diagnosed AML and ≤ 65 yo with 1 st relapse AML and ECOG PS= 0-2, S CR &lt; 2.0 mg/dL, total bilirubin &lt; 2.0 mg/dL, ALT/AST &lt;3x ULN, and LVEF ≥ 50% were eligible. Pts with APL, DNR exposure &gt;368 mg/m 2 , active CNS leukemia, and uncontrolled infections were excluded. Pts were randomized 2:1 to receive up to 2 inductions and 2 consolidations with CPX-351 (100 u/m 2 ; D 1, 3, 5) or CYT + DNR (7+3) for newly diagnosed pts or investigator’s choice of salvage chemotherapy for relapsed pts. Allogeneic transplantation was permitted. Univariate and multivariate Cox and logistic regression were used to assess associations between baseline characteristics and overall (OS) and event-free survival (EFS) and 60-day mortality for all pts. The multivariate employed stepwise selection to identify statistically significant prognostic factors after accounting for potential treatment effects. Results: Patient characteristics including cytogenetics were well balanced. Significant negative prognostic factors affecting OS, EFS, and 60-day mortality included relapsed disease (Study 205 participation, HR=2.13, p&lt;0.001), adverse cytogenetics (HR=1.52, p=0.024), and low (&lt;3g/dL) serum albumin (HR=1.82, p=0.005). CPX-351 treatment was a significant positive factor in EFS (HR=0.62, p=0.006). Conclusions: This analysis identified and quantitated disease specific (adverse cytogenetics) and patient specific (albumin&lt;3gm/dL) factors that can be used to better design future studies. Clinical trial information: NCT00788892 and NCT00822094.
Breast cancer patient surveillance following curative-intent treatment: Variation among metropolitan statistical areas.
Authors: Robert J. Avino, Emad S. Allam, Ling Chen, Katherine S. Virgo, Julie A. Margenthaler, Frank E. Johnson
Journal: Journal of Clinical Oncology (2013)

6526 Background: There are about 3 million breast cancer survivors in the US, with about 230,000 new cases of breast cancer diagnosed annually. Most receive curative-intent treatment. Post-treatment surveillance is commonly done. We previously documented dramatic variation in surveillance intensity among ASCO experts. The only surveillance modalities endorsed by ASCO for asymptomatic patients are office visit and mammogram. We sought to determine the effect of the physician’s practice location on the intensity of surveillance by comparing Metropolitan Statistical Areas (MSAs). MSAs are large urbanized areas. Methods: The 3245 ASCO members who indicated that breast cancer was a major clinical focus of their practice were surveyed regarding their surveillance practices. They were asked to consider 4 idealized clinical vignettes and indicate their surveillance plan for each. A menu of 12 testing modalities was offered. Repeated-measures ANOVA was employed to compare practice patterns by MSA. Results: There were 1012 responses; 915 were evaluable. The modalities most frequently recommended were office visit, CBC, LFTs, and mammogram. We analyzed the 8 MSAs (New York, Chicago, Philadelphia, Los Angeles, Pittsburgh, Washington, Boston, and St. Louis) with enough responses for analysis. Every modality discouraged by ASCO was recommended by some respondents. Significant variation (p&lt;0.05) in recommended frequency of use was present for all frequently recommended surveillance modalities. For example, in year 1, office visit was recommended 2.8 ± 0.9 (mean ±SD) times in Philadelphia and 4.0 ± 1.9 times in Los Angeles. Conclusions: Evidence-based clinical guidelines have proven effective in providing high quality care and decreasing variation in practice.ASCO members often recommend surveillance modalities that are not recommended by ASCO clinical guidelines, suggesting overuse. Statistically significant variation among the 8 MSAs in recommended use of most testing modalities was present. However, this variation was clinically quite small. Variation among MSAs cannot explain the known marked variation in clinical practice we have previously documented.